The Role of Cytokines in Predicting the Efficacy of Acute Stage Treatment in Patients with Schizophrenia

References

• Andrade C. Anti-inflammatory strategies in the treatment of schizophrenia. Expert Rev Clin Pharmacol. 2016;9(2):161–163. doi:10.1586/17512433.2016.109508626427750
   PubMed Web of Science ®Google Scholar
• Smyth AM, Lawrie SM. The neuroimmunology of schizophrenia. Clin Psychopharmacol Neurosci. 2013;11(3):107–117. doi:10.9758/cpn.2013.11.3.10724465246
   PubMed Web of Science ®Google Scholar
• Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1. doi:10.1038/nrdp.2015.67.
   Web of Science ®Google Scholar
• McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30(1):67–76. doi:10.1093/epirev/mxn00118480098
   PubMed Web of Science ®Google Scholar
• Harvey PD, Strassnig MT. Cognition and disability in schizophrenia: cognition-related skills deficits and decision-making challenges add to morbidity. World Psychiatry. 2019;18(2):165–167. doi:10.1002/wps.v18.231059625
   PubMed Web of Science ®Google Scholar
• Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195–1203. doi:10.1093/schbul/sby05829762765
   PubMed Web of Science ®Google Scholar
• Harvey PD, Strassnig M. Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status. World Psychiatry. 2012;11(2):73–79. doi:10.1016/j.wpsyc.2012.05.00422654932
   PubMed Web of Science ®Google Scholar
• Keshavan MS, Lawler AN, Nasrallah HA, et al. New drug developments in psychosis: challenges, opportunities and strategies. Prog Neurobiol. 2017;152:3–20. doi:10.1016/j.pneurobio.2016.07.00427519538
   PubMed Web of Science ®Google Scholar
• Li CY, Tao H, Yang X, et al. Assessment of a combination of serum proteins as potential biomarkers to clinically predict schizophrenia. Int J Med Sci. 2018;15(9):900–906. doi:10.7150/ijms.2434630008602
   PubMed Web of Science ®Google Scholar
• Orsolini L, Sarchione F, Vellante F, et al. Protein-C reactive as biomarker predictor of schizophrenia phases of illness? A systematic review. Curr Neuropharmacol. 2018;16(5):583–606. doi:10.2174/1570159X1666618011914453829357805
   PubMed Web of Science ®Google Scholar
• Mednick SA, Machon RA, Huttunen MO, Bonett D. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry. 1988;45(2):189–192. doi:10.1001/archpsyc.1988.018002601090133337616
   PubMed Web of Science ®Google Scholar
• Cullen AE, Holmes S, Pollak TA, et al. Associations between non-neurological autoimmune disorders and psychosis: a meta-analysis. Biol Psychiatry. 2019;85(1):35–48. doi:10.1016/j.biopsych.2018.06.01630122288
   PubMed Web of Science ®Google Scholar
• Bagaric D, Brečić P, Ostojić D, et al. The relationship between depressive syndrome and suicidal risk in patients with acute schizophrenia. Croat Med J. 2013;54(5):436–443. doi:10.3325/cmj.2013.54.43624170722
   PubMed Web of Science ®Google Scholar
• Ripke S, Neale BM, Corvin A. Biological insights from 108 shizophrenia-associated genetic loci. Nature. 2014;511(7510):421-+.
   Web of Science ®Google Scholar
• Benros ME, Mortensen PB, Eaton WW. Autoimmune diseases and infections as risk factors for schizophrenia. Neuroimmunomodulation Health Dis. 2012;1262:56–66.
   Web of Science ®Google Scholar
• Lesh TA, Careaga M, Rose DR, et al. Cytokine alterations in first-episode schizophrenia and bipolar disorder: relationships to brain structure and symptoms. J Neuroinflammation. 2018;15. doi:10.1186/s12974-018-1197-2.
   Web of Science ®Google Scholar
• Fillman SG, Weickert TW, Lenroot RK, et al. Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca’s area volume. Mol Psychiatry. 2016;21(8):1090–1098. doi:10.1038/mp.2015.9026194183
   PubMed Web of Science ®Google Scholar
• Hoseth EZ, Ueland T, Dieset I, et al. A study of TNF pathway activation in schizophrenia and bipolar disorder in plasma and brain tissue. Schizophr Bull. 2017;43(4):881–890. doi:10.1093/schbul/sbw18328049760
   PubMed Web of Science ®Google Scholar
• Muller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002;159(6):1029–1034. doi:10.1176/appi.ajp.159.6.102912042193
   PubMed Web of Science ®Google Scholar
• Sommer IE, de Witte L, Begemann M, et al. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry. 2012;73(4):414–419. doi:10.4088/JCP.10r0682322225599
   PubMed Web of Science ®Google Scholar
• Tang HP, Panemangalore R, Yarde M, et al. 384-well multiplexed luminex cytokine assays for lead optimization. J Biomol Screen. 2016;21(6):548–555. doi:10.1177/108705711664416427095819
   PubMedGoogle Scholar
• Wallwork RS, Fortgang R, Hashimoto R, et al. Searching for a consensus five-factor model of the positive and negative syndrome scale for schizophrenia. Schizophr Res. 2012;137(1–3):246–250. doi:10.1016/j.schres.2012.01.03122356801
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696–1709. doi:10.1038/mp.2016.326903267
   PubMed Web of Science ®Google Scholar
• Lee EE, Hong S, Martin AS, et al. Inflammation in schizophrenia: cytokine levels and their relationships to demographic and clinical variables. Am J Geriatr Psychiatry. 2017;25(1):50–61. doi:10.1016/j.jagp.2016.09.00927840055
   PubMed Web of Science ®Google Scholar
• Dahan S, Bragazzi NL, Yogev A, et al. The relationship between serum cytokine levels and degree of psychosis in patients with schizophrenia. Psychiatry Res. 2018;268:467–472. doi:10.1016/j.psychres.2018.07.04130138859
   PubMed Web of Science ®Google Scholar
• Akira S, Kishimoto T, Akira S. NF-IL6 and NF-kappa B in cytokine gene regulation. Adv Immunol. 1997;65:1–46.9238507
   PubMed Web of Science ®Google Scholar
• Thiel G, Ulrich M, Mukaida N, et al. Resveratrol stimulation induces interleukin-8 gene transcription via NF-kappa B. Pharmacol Res. 2018;134:238–245. doi:10.1016/j.phrs.2018.07.00330018026
   PubMed Web of Science ®Google Scholar
• Thomas R. The TRAF6-NF kappa B signaling pathway in autoimmunity: not just inflammation. Arthritis Res Ther. 2005;7(4):170–173. doi:10.1186/ar178415987501
   PubMed Web of Science ®Google Scholar
• Kim YK, Kim L, Lee MS. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res. 2000;44(3):165–175. doi:10.1016/S0920-9964(99)00171-110962218
   PubMed Web of Science ®Google Scholar
• Strassnig M, Bowie C, Pinkham AE, et al. Which levels of cognitive impairments and negative symptoms are related to functional deficits in schizophrenia? J Psychiatr Res. 2018;104:124–129. doi:10.1016/j.jpsychires.2018.06.01830029051
   PubMed Web of Science ®Google Scholar
• Harvey PD. Assessing disability in schizophrenia: tools and contributors. J Clin Psychiatr. 2014;75(10):e27. doi:10.4088/JCP.13049tx5c
   Google Scholar
• Rocca P, Montemagni C, Zappia S, Piterà R, Sigaudo M, Bogetto F. Negative symptoms and everyday functioning in schizophrenia: a cross-sectional study in a real world-setting. Psychiatry Res. 2014;218(3):284–289. doi:10.1016/j.psychres.2014.04.01824814140
   PubMed Web of Science ®Google Scholar
• Davis MC, Horan WP, Marder SR. Psychopharmacology of the negative symptoms: current status and prospects for progress. Eur Neuropsychopharmacol. 2014;24(5):788–799. doi:10.1016/j.euroneuro.2013.10.01024252823
   PubMed Web of Science ®Google Scholar
• Siris SG. Depression in schizophrenia: perspective in the era of “Atypical” antipsychotic agents. Am J Psychiatry. 2000;157(9):1379–1389. doi:10.1176/appi.ajp.157.9.137910964850
   PubMed Web of Science ®Google Scholar
• Menendez-Miranda I, Garcia-Portilla MP, Garcia-Alvarez L, et al. Predictive factors of functional capacity and real-world functioning in patients with schizophrenia. Eur Psychiatry. 2015;30(5):622–627. doi:10.1016/j.eurpsy.2014.12.01125681175
   PubMed Web of Science ®Google Scholar
• Maes M, Stevens W, Scharpe S. Seasonal variation in peripheral blood leukocyte subsets and in serum interleukin-6, and soluble interleukin-2 and −6 receptor concentrations in normal volunteers. Experientia. 1994;50(9):821–829.7523180
   PubMedGoogle Scholar
• Marsland AL, Gianaros PJ, Abramowitch SM, Manuck SB, Hariri AR. Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry. 2008;64(6):484–490. doi:10.1016/j.biopsych.2008.04.01618514163
   PubMed Web of Science ®Google Scholar
• Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science. 2003;302(5651):1760–1765. doi:10.1126/science.108841714615545
   PubMed Web of Science ®Google Scholar
• Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–457. doi:10.1016/j.biopsych.2009.09.03320015486
   PubMed Web of Science ®Google Scholar
• Young JJ, Bruno D, Pomara N. A review of the relationship between proinflammatory cytokines and major depressive disorder. J Affect Disord. 2014;169:15–20. doi:10.1016/j.jad.2014.07.03225128861
   PubMed Web of Science ®Google Scholar
• Gonzalez-Blanco L, Garcia-Portilla MP, Dal Santo F, et al. Predicting real-world functioning in outpatients with schizophrenia: role of inflammation and psychopathology. Psychiatry Res. 2019;280:112509. doi:10.1016/j.psychres.2019.11250931446217
   PubMed Web of Science ®Google Scholar
• Santesteban-Echarri O, Paino M, Rice S, et al. Predictors of functional recovery in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies. Clin Psychol Rev. 2017;58:59–75. doi:10.1016/j.cpr.2017.09.00729042139
   PubMed Web of Science ®Google Scholar
• Brown AS, Hooton J, Schaefer CA, et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry. 2004;161(5):889–895. doi:10.1176/appi.ajp.161.5.88915121655
   PubMed Web of Science ®Google Scholar
• Ellman LM, Deicken RF, Vinogradov S, et al. Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr Res. 2010;121(1–3):46–54. doi:10.1016/j.schres.2010.05.01420553865
   PubMed Web of Science ®Google Scholar
• Girgis RR, Kumar SS, Brown AS. The cytokine model of schizophrenia: emerging therapeutic strategies. Biol Psychiatry. 2014;75(4):292–299. doi:10.1016/j.biopsych.2013.12.00224439555
   PubMed Web of Science ®Google Scholar
• Kogan S, Ospina LH, Kimhy D. Inflammation in individuals with schizophrenia - Implications for neurocognition and daily function. Brain Behav Immun. 2018;74:296–299. doi:10.1016/j.bbi.2018.09.01630218782
   PubMed Web of Science ®Google Scholar
• Miller BJ, Dias JK, Lemos HP, et al. An open-label, pilot trial of adjunctive tocilizumab in schizophrenia. J Clin Psychiatry. 2016;77(2):275–276. doi:10.4088/JCP.15l0992026930525
   PubMed Web of Science ®Google Scholar
• Girgis RR, Ciarleglio A, Choo T, et al. A randomized, double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia. Neuropsychopharmacology. 2018;43(6):1317–1323. doi:10.1038/npp.2017.25829090685
   PubMed Web of Science ®Google Scholar
• Maes M, Chiavetto LB, Bignotti S, et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol. 2000;10(2):119–124. doi:10.1016/S0924-977X(99)00062-010706993
   PubMed Web of Science ®Google Scholar
• Tourjman V, Kouassi É, Koué M-È, et al. Antipsychotics’ effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr Res. 2013;151(1–3):43–47. doi:10.1016/j.schres.2013.10.01124200418
   PubMed Web of Science ®Google Scholar